Santander-Backed Ebury in Talks to Buy FX Rival Lumon in £100m-Plus Deal
Ebury, the cross-border payments and foreign exchange business majority-owned by Banco Santander, is in talks to acquire UK foreign exchange specialist Lumon in a deal that could value the target at more than £100m, according to a report by City AM. The discussions are with Pollen Street Capital, Lumon's owner since 2013, and neither party has confirmed a transaction. There is no certainty a deal will be agreed.
The significance is less in the price than in the signal. Ebury raised roughly £550m earlier this year from investors including Santander and Centerbridge, capital explicitly earmarked for expansion across products and geographies. Lumon would be the first substantial deployment of that money, and it tells the market that Ebury intends to buy scale rather than build it.
Lumon provides foreign exchange and international payments services to both consumers and corporates, and has itself been an acquirer under private equity ownership, buying Abacus FX in 2024 and UK payments specialist Fiscal FX this year. Pollen Street appointed Canaccord Genuity to run a sale process earlier in 2026 after an earlier prospective buyer withdrew, which puts Ebury in the position of a second-round bidder for an asset already shopped around the market.
For Santander, the strategic logic is straightforward. The Spanish group took majority control of Ebury in 2019 and has used it as its SME cross-border franchise, a business that sits alongside the bank's corporate arm without cannibalising it. Bolting on Lumon adds volume, client relationships and a consumer-facing FX book to a platform Santander already consolidates. Vitruvian Partners and Ebury's founders retain significant minority stakes.
The deal also lands squarely in a consolidating sector. Cross-border FX and payments has become a scale game, with margins compressed by transparent pricing, embedded finance competitors and the operating cost of maintaining licences across multiple jurisdictions. Mid-sized independents such as Lumon face a choice between selling and being outspent, and sponsors that bought into the space a decade ago are looking for exits.
The IPO question is the more interesting one. Ebury has been circling a London listing for years, targeting a valuation around £2bn, and shelved those plans after market volatility in 2025 before pivoting to a private capital raise. An acquisition at this point suggests the listing remains parked rather than imminent, with the company choosing to build revenue and market share first and take the story to public investors later, from a stronger position.
That is a defensible sequence, but it carries execution risk. Ebury would be integrating a second business while absorbing a large funding round, in a market where the acquirer is under pressure to demonstrate that consolidated volume translates into consolidated margin. Whether it does will determine what any eventual London listing is actually worth.
